Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2025 Mar 11;104(5):e213401.
doi: 10.1212/WNL.0000000000213401. Epub 2025 Feb 14.

Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia

Liset de Boer  1 , Jackie M Poos  1 , Esther Van Den Berg  1 , Julie F H De Houwer  1 , Tine Swartenbroekx  1 , Elise G P Dopper  1 , Pam Boesjes  1 , Najlae Tahboun  1 , Arabella Bouzigues  2 , Phoebe H Foster  2 , Eve Ferry-Bolder  2 , Kerala Adams-Carr  2 , Lucy L Russell  2 , Rhian S Convery  2 , Jonathan D Rohrer  2 , Harro Seelaar  1 , Lize C Jiskoot  1
Affiliations
Comparative Study

Montreal Cognitive Assessment vs the Mini-Mental State Examination as a Screening Tool for Patients With Genetic Frontotemporal Dementia

Liset de Boer et al. Neurology. .

Abstract

Background and objectives: With upcoming clinical trials targeting preclinical stages of genetic frontotemporal dementia (FTD), early detection through cognitive screening is crucial. The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) have potential as screening instruments for early-stage genetic FTD. However, no comparative evaluation has been performed. We aimed to compare MMSE and MoCA performance among presymptomatic, prodromal, and symptomatic pathogenic variant carriers to analyze which screening test has superior discriminative abilities.

Methods: We used cross-sectional and longitudinal data from 2 longitudinal genetic FTD cohort studies in the Netherlands and the United Kingdom, collected between 2021 and 2024. Participants were either presymptomatic, prodromal, or symptomatic pathogenic variant carriers or healthy controls (first-degree family members without pathogenic variants for FTD). Grouping was based on the global CDR-plus-NACC-FTLD score. Participants were assessed with both MoCA and MMSE. Statistical analyses compared total and subscores between groups and evaluated predictive and classification accuracy of both tests.

Results: A total of 243 participants (mean age 49.9 ± 13.1 years, mean education 14.5 ± 3.0 years, 56% female), 157 of whom were pathogenic variant carriers (MAPT, GRN, C9orf72, TARDBP, and TBK1) and 86 controls, were included. Carriers were classified as presymptomatic (n = 119), prodromal (n = 18), or symptomatic (n = 20). Both MoCA [F(3,239) = 16.565, p < 0.001] and MMSE [F(3,239) = 13.529, p < 0.001] total scores differed significantly between groups, with controls (median MoCA 28.5, 95% CI 28.0-29.0; median MMSE 30, 95% CI 30.0-30.0) outperforming prodromal (median MoCA 26, 95% CI 23.0-27.0; median MMSE 29, 95% CI 27.5-29.5) and symptomatic (median MoCA 20.5, 95% CI 17.0-24.0; median MMSE 26, 95% CI 23.5-29.0) carriers. MoCA distinguished between presymptomatic carriers and controls (median MoCA 28, 95% CI 27.0-29.0), but MMSE did not. MoCA demonstrated superior discriminative ability compared with MMSE (MoCA area under the curve [AUC] = 0.87, 95% CI 0.81-0.94; MMSE AUC = 0.80, 95% CI 0.72-0.89).

Discussion: Its higher sensitivity and better discriminative power make MoCA a more valuable tool for cognitive screening in upcoming clinical trials targeting preclinical FTD. Future studies should aim for larger sample sizes from additional study centers.

PubMed Disclaimer

Conflict of interest statement

The authors report no relevant disclosures. Go to Neurology.org/N for full disclosures.

Figures

Figure 1
Figure 1. Differences in MoCA and MMSE Performance Between Clinical Groups
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
Figure 2
Figure 2. Comparison MoCA and MMSE Between Clinical Groups
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
Figure 3
Figure 3. Differences in MoCA and MMSE Performance Between Genetic Groups
C9orf72 = chromosome 9 open reading frame 72; CDR = CDR-plus-NACC-FTLD; GRN = progranulin; MAPT = microtubule-associated protein tau; MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
Figure 4
Figure 4. ROC Curves for Both MMSE and MoCA per Group
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
Figure 5
Figure 5. Mean Performance per Clinical Group
MMSE = Mini-Mental State Examination; MoCA = Montreal Cognitive Assessment.
See this image and copyright information in PMC

References

    1. Olney NT, Ong E, Goh SYM, et al. . Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement. 2020;16(1):49-59. doi:10.1016/j.jalz.2019.08.196 - DOI - PMC - PubMed
    1. Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456-2477. doi:10.1093/brain/awr179 - DOI - PMC - PubMed
    1. Rohrer JD, Warren JD. Phenotypic signatures of genetic frontotemporal dementia. Curr Opin Neurol. 2011;24(6):542-549. doi:10.1097/WCO.0b013e32834cd442 - DOI - PubMed
    1. Rohrer JD, Warren JD, Fox NC, Rossor MN. Presymptomatic studies in genetic frontotemporal dementia. Revue Neurologique. 2013;169(10):820-824. doi:10.1016/j.neurol.2013.07.010 - DOI - PMC - PubMed
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. doi:10.1016/0022-3956(75)90026-6 - DOI - PubMed

Publication types

Substances

LinkOut - more resources